Israeli healthtech startup Notal Vision secures $25M to provide better methods of detecting age-related macular degeneration

Notal Vision, a Tel-Aviv, Israel-based healthtech startup focused on advancing eye care with precision medicine by extending disease management from the clinic to the home, has raised $25 million in funding to support the commercial growth of the company’s current service, ForeseeHome AMD Monitoring Program, as well as further research and development efforts for pipeline technologies. The funding was led by existing investor Ganot Capital.

Founded in 2000 by Barak Azmon and Yair Alster, Notal Vision is developing the first comprehensive diagnostic solution for the early detection and frequent monitoring of Age-Related Macular Degeneration (AMD), the leading cause of blindness in the western world today. Notal Vision’s platform leverages AI-enabled analyses of high-volume personalized health data that extends disease management from the clinic to the home to improve vision outcomes, reduce treatment burden, and improve health economics.

Early detection of ARM can allow doctors to treat patients at an earlier stage and possibly prevent any loss of sight. A true pioneer in the eye care industry, Notal Vision has developed and introduced the first home-based monitoring system for AMD patients, the ForeseeHome™ AMD Monitoring Program.

“Pursuing additional funding has allowed us to expand our ForeseeHome field-based sales team,” explains CEO Kester Nahen, PhD. “We have a proven model that includes low-cost medical devices, an effective artificial intelligence (AI)-driven decision support solution, and a dependable clinical patient engagement platform. With the additional investment, we believe we will be able to prove that partnering with accounts as an extension of their practice will drive deeper adoption of our home diagnostic services.”

The company is also well funded to continue development of the Home OCT platform. Receiving FDA Breakthrough Device status at the end of 2018, and with efforts to establish reimbursement well under way, the home-based OCT will help address the high unmet monitoring need for physicians and their patients alongside anti-VEGF therapy.

“Notal Vision is uniquely positioned to continue to lead the ophthalmic home diagnostic services market.” says Guy Kastav, Chairman of the Board of Notal Vision. “Ganot Capital is an investment company dedicated to improving quality of life for senior citizens. Ganot Capital believes it’s important to help Notal Vision succeed in their mission to help prevent blindness through age-related retinal diseases.”